scholarly journals Author Correction: Health state dependent multiphoton induced autofluorescence in human 3D in vitro lung cancer model

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Vasyl Kilin ◽  
Christophe Mas ◽  
Samuel Constant ◽  
Jean-Pierre Wolf ◽  
Luigi Bonacina
Keyword(s):  
Lung Cancer ◽  
Health State ◽  
Cancer Model ◽  
State Dependent ◽  
Lung Cancer Model

scholarly journals Health state dependent multiphoton induced autofluorescence in human 3D in vitro lung cancer model

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Vasyl Kilin ◽  
Christophe Mas ◽  
Samuel Constant ◽  
Jean-Pierre Wolf ◽  
Luigi Bonacina
Keyword(s):  
Lung Cancer ◽  
Health State ◽  
Cancer Model ◽  
State Dependent ◽  
Lung Cancer Model

scholarly journals The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Lyndsey A. Reich ◽  
Jessica A. Moerland ◽  
Ana S. Leal ◽  
Di Zhang ◽  
Sarah Carapellucci ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Tumor Development ◽  
Metastatic Breast ◽  
In Vitro Assays ◽  
Cancer Model ◽  
Lung Cancer Model ◽  
Model Treatment ◽  
X Receptors

AbstractRexinoids are ligands which activate retinoid X receptors (RXRs), regulating transcription of genes involved in cancer-relevant processes. Rexinoids have anti-neoplastic activity in multiple preclinical studies. Bexarotene, used to treat cutaneous T cell lymphoma, is the only FDA-approved rexinoid. Bexarotene has also been evaluated in clinical trials for lung and metastatic breast cancer, wherein subsets of patients responded despite advanced disease. By modifying structures of known rexinoids, we can improve potency and toxicity. We previously screened a series of novel rexinoids and selected V-125 as the lead based on performance in optimized in vitro assays. To validate our screening paradigm, we tested V-125 in clinically relevant mouse models of breast and lung cancer. V-125 significantly (p < 0.001) increased time to tumor development in the MMTV-Neu breast cancer model. Treatment of established mammary tumors with V-125 significantly (p < 0.05) increased overall survival. In the A/J lung cancer model, V-125 significantly (p < 0.01) decreased number, size, and burden of lung tumors. Although bexarotene elevated triglycerides and cholesterol in these models, V-125 demonstrated an improved safety profile. These studies provide evidence that our screening paradigm predicts novel rexinoid efficacy and suggest that V-125 could be developed into a new cancer therapeutic.

Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo

2020 ◽  
Vol 28 (9) ◽  
pp. 961-969 ◽  
Author(s):  
Mingting Wang ◽  
Qin Zeng ◽  
Yuan Li ◽  
Saber Imani ◽  
Danna Xie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Model ◽  
Lung Cancer Model

scholarly journals The Rexinoid V-125 Reduces Tumor Growth in Preclinical Models of Breast and Lung Cancer

2021 ◽  
Author(s):  
Lyndsey A. Reich ◽  
Jessica A. Moerland ◽  
Ana Leal ◽  
Di Zhang ◽  
Sarah Carapellucci ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Tumor Development ◽  
Metastatic Breast ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Lung Cancer Model ◽  
Model Treatment ◽  
X Receptors

Abstract Rexinoids are ligands which activate retinoid X receptors (RXRs), regulating transcription of genes involved in cancer-relevant processes. Rexinoids have anti-neoplastic activity in multiple preclinical studies. Bexarotene, used to treat cutaneous T cell lymphoma, is the only FDA-approved rexinoid. Bexarotene has also been evaluated in clinical trials for lung and metastatic breast cancer, wherein subsets of patients responded despite advanced disease. By modifying structures of known rexinoids, we can improve potency and toxicity. We previously screened a series of novel rexinoids and selected V-125 as the lead based on performance in optimized in vitro assays. To validate our screening paradigm, we tested V-125 in clinically relevant mouse models of breast and lung cancer. V-125 significantly (p < 0.001) increased time to tumor development in the MMTV-Neu breast cancer model. Treatment of established mammary tumors with V-125 significantly (p < 0.05) increased overall survival. In the A/J lung cancer model, V-125 significantly (p < 0.01) decreased number, size, and burden of lung tumors. Although bexarotene elevated triglycerides and cholesterol in these models, V-125 demonstrated an improved safety profile. These studies provide evidence that our screening paradigm predicts novel rexinoid efficacy and suggest that V-125 could be developed into a new cancer therapeutic.

scholarly journals DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model

Gene Therapy ◽  
2014 ◽  
Vol 21 (10) ◽  
pp. 888-896 ◽  
Author(s):  
T-Y Weng ◽  
M-C Yen ◽  
C-T Huang ◽  
J-J Hung ◽  
Y-L Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Transgenic Mouse ◽  
Dna Vaccine ◽  
Mouse Lung ◽  
Cancer Model ◽  
Antitumor Response ◽  
Lung Cancer Model

Refinement of an Orthotopic Lung Cancer Model in the Nude Rat

2001 ◽  
Vol 38 (5) ◽  
pp. 483-490 ◽  
Author(s):  
T. H. March ◽  
P. G. Marron-Terada ◽  
S. A. Belinsky
Keyword(s):  
Lung Cancer ◽  
Cancer Model ◽  
Nude Rat ◽  
Lung Cancer Model

scholarly journals Combination Therapy of VEGF-Trap and Gemcitabine Results in Improved Anti-Tumor Efficacy in a Mouse Lung Cancer Model

PLoS ONE ◽  
2013 ◽  
Vol 8 (7) ◽  
pp. e68589 ◽  
Author(s):  
Shuang Zhou ◽  
Yang Yang ◽  
Yaoqin Yang ◽  
Huihong Tao ◽  
Dong Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Combination Therapy ◽  
Mouse Lung ◽  
Cancer Model ◽  
Lung Cancer Model ◽  
Vegf Trap

scholarly journals Hyaluronate Functionalized Multi-Wall Carbon Nanotubes Filled with Carboplatin as a Novel Drug Nanocarrier against Murine Lung Cancer Cells

Nanomaterials ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. 1572 ◽  
Author(s):  
Daniel Salas-Treviño ◽  
Odila Saucedo-Cárdenas ◽  
María de Jesús Loera-Arias ◽  
Humberto Rodríguez-Rocha ◽  
Aracely García-García ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Carbon Nanotubes ◽  
Tumor Cells ◽  
Therapeutic Potential ◽  
Cell Uptake ◽  
In Vivo Models ◽  
Multi Wall Carbon Nanotubes ◽  
Lung Cancer Model

Carbon nanotubes (CNTs) have emerged in recent years as a potential option for drug delivery, due to their high functionalization capacity. Biocompatibility and selectivity using tissue-specific biomolecules can optimize the specificity, pharmacokinetics and stability of the drug. In this study, we design, develop and characterize a drug nanovector (oxCNTs-HA-CPT) conjugating oxidated multi-wall carbon nanotubes (oxCNTs) with hyaluronate (HA) and carboplatin (CPT) as a treatment in a lung cancer model in vitro. Subsequently, we exposed TC–1 and NIH/3T3 cell lines to the nanovectors and measured cell uptake, cell viability, and oxidative stress induction. The characterization of oxCNTs-HA-CPT reveals that on their surface, they have HA. On the other hand, oxCNTs-HA-CPT were endocytosed in greater proportion by tumor cells than by fibroblasts, and likewise, the cytotoxic effect was significantly higher in tumor cells. These results show the therapeutic potential that nanovectors possess; however, future studies should be carried out to determine the death pathways involved, as well as their effect on in vivo models.

Sign in / Sign up

Export Citation Format

Share Document